Efficacy of Pediococcus acidilactici CCFM6432 in alleviating anhedonia in major depressive disorder: A randomized controlled trial

Table 2 Between-group comparison of clinical assessments using mixed-design analysis of variance (mean ± SD)

	CCFM6432 (n = 27)	Placebo (n = 28)	P value1	P value2	P value3
HAMA_Baseline	19.07 (7.80)	18.11 (9.39)	0.011	0.455	< 0.001
HAMA_Follow-up	9.04 (5.89)	12.89 (7.95)
HAMD_Baseline	21.74(7.07)	21.04 (8.69)	0.013	0.492	< 0.001
HAMD_Follow-up	9.89 (5.80)	13.25 (8.72)
TEPS_Baseline	70.07 (11.89)	71.89 (13.87)	0.041	0.645	0.007
TEPS_Follow-up	78.00 (13.92)	73.07 (15.22)
ANT_Baseline	30.56 (6.45)	33.00 (7.09)	0.015	0.981	0.009
ANT_Follow-up	35.74 (7.15)	33.21 (8.01)
CON_Baseline	39.52 (7.63)	38.89 (9.33)	0.293	0.486	0.031
CON_Follow-up	42.26 (8.03)	39.86 (9.16)

¹P-value for the group × time interaction.

²P-value for the main effect of group.

³P-value for the main effect of time.

ANT: Anticipatory; CON: Consummatory; HAMA: Hamilton Anxiety Rating Scale; HAMD: Hamilton Depression Rating Scale; TEPS: Temporal Experience of Pleasure Scale.